New Delhi: According to the second big news of the morning, now Dr. Krishna Aila, Chairman and Managing Director of Bharat Biotech, has told on Saturday that Phase 3 of the clinical trial of Corona’s Nasal Vaccine has now been completed and the company will be in the next month. It will submit its necessary data to the Drug Controller General of India (DGCA).
In this regard, Dr. Ella exulted and said that after the completion of the clinical trial, data analysis is also being done. As soon as the above analysis is completed, its data will also be handed over to DGCA. In such a situation, if all goes well, then we will be able to launch the world’s first nasal covid vaccine.
Dr. Ella was in Paris as a speaker at Viva Technology 2022, where India was declared the Country of the Year. He said that “The booster dose of the vaccine gives immunity. I always say that a booster dose is a miracle dose for every vaccination. Corona will always be there and we have to live with it and handle it and control it more intelligently.”
